查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529695

帶狀皰疹疫苗市場規模、佔有率、趨勢分析報告：按產品、類型、最終用途、地區和細分市場預測，2024-2030 年

Shingles Vaccine Market Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax), By Type (Recombinant Vaccine), By End-use (Private Healthcare Settings), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

帶狀皰疹疫苗市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球帶狀皰疹疫苗市場規模預計將達到112.6億美元，預測期內複合年成長率為15.34%。

已開發國家帶狀皰疹發病率的增加和對帶狀皰疹的高度認知正在促進市場擴張。據 CDC 稱，美國每年報告近 100 萬例帶狀皰疹病例。此外，據估計，該國三分之一的人在一生中會患上這種疾病。

預計疫苗的越來越多的採用以及各個政府監管機構對疫苗接種的更多建議將在預測期內推動市場發展。例如，2019年2月，英國免疫聯合委員會（JCVI）建議使用重組疫苗來預防60至70歲成年人的帶狀皰疹。

一些國家將帶狀皰疹疫苗納入國家免疫計畫預計將推動疫苗需求。例如，在英國，帶狀皰疹疫苗自2013年起已成為國家免疫計畫的一部分。英國是歐洲第一個將帶狀皰疹疫苗納入國家免疫計畫的國家，一劑疫苗的國家醫療服務體系 (NHS) 費用約為 130 美元。同樣，美國、義大利、澳洲、加拿大幾個省份和韓國等其他國家也已將該疫苗納入其免疫計畫。

在其他地方，在新興市場，市場相關人員和監管機構積極努力提高對風險族群的意識，預計將支持未來幾年的市場成長。例如，葛蘭素史克公司發起了宣傳活動，透過教育人們了解疫苗接種的好處來提高老年人的疫苗接種率。

該疫苗的高效能預計將在預測期內增加其使用量。根據臨床試驗結果，Shingrix對於預防帶狀皰疹和帶狀皰疹後遺症神經痛非常有效。兩劑 Shingrix 對 50 歲及以上成年人預防癌症的效果超過 90%。接種疫苗後，85%以上的預防效果持續至少4年。

疫苗的低價供應以及已開發國家的高發病率和高疫苗接種覆蓋率預計將推動市場成長。英國、美國、法國、加拿大、德國和韓國的帶狀皰疹疫苗接種率高於其他國家。例如，英國皰疹疫苗接種覆蓋率最高，超過 60% 的符合條件的成年人接種了疫苗。

帶狀皰疹疫苗市場報告亮點

  • 以產品來看， 定序在2023年佔據最大佔有率。此外，隨著監管機構對帶狀皰疹預防的建議不斷增加，Shingrix 預計在預測期內將以顯著的複合年成長率成長。
  • 按疫苗類型分類，由於重組疫苗相關風險較低，預計重組疫苗領域在預測期內將顯著成長。
  • 由於未滿足的需求較多以及疫苗接種計劃的推出取得進展，預計亞太地區將在預測期內成長最快。
  • 由於有利的報銷政策以及不斷提高醫療保健專業人員和患者意識的舉措，北美在 2023 年佔據了市場主導地位。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章：帶狀皰疹疫苗市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 帶狀皰疹疫苗市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析

第 4 章：帶狀皰疹疫苗市場：按產品估計和趨勢分析

  • 全球帶狀皰疹疫苗市場：按產品分類的儀表板
  • 全球帶狀皰疹疫苗市場：按產品分類的波動分析
  • 全球帶狀皰疹疫苗市場：按產品分類的收益
  • 定序
  • 佐斯塔瓦克斯
  • 斯基佐斯特

第5章帶狀皰疹疫苗市場：按類型估計和趨勢分析

  • 全球帶狀皰疹疫苗市場：按類型分類的儀表板
  • 全球帶狀皰疹疫苗市場：按類型波動分析
  • 全球帶狀皰疹疫苗市場：按類型分類的收益
  • 重組疫苗
  • 減毒活疫苗

第6章帶狀皰疹疫苗市場：最終用途的估計和趨勢分析

  • 全球帶狀皰疹疫苗市場：按最終用途分類的儀表板
  • 全球帶狀皰疹疫苗市場：最終用途的波動分析
  • 全球帶狀皰疹疫苗市場：按最終用途分類的收益
  • 私人醫療機構
  • 政府醫療保健網站

第 7 章：帶狀皰疹疫苗市場：按產品、類型和最終用途分類的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭格局

  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • GlaxoSmithKline plc.
    • Merck &Co., Inc.
    • SK chemicals
    • Green Cross Corp
    • Geneone Life Science
    • Vaccitech
    • CanSinoBIO
Product Code: GVR-4-68039-638-0

Shingles Vaccine Market Growth & Trends:

The global shingles vaccine market size is expected to reach USD 11.26 billion by 2030, registering a CAGR of 15.34% during the forecast period, according to a new report by Grand View Research, Inc. Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth. According to the CDC, nearly one million cases of shingles are reported each year in the United States. Furthermore, one out of three individuals in the country will develop the disease in their lifetime.

The increasing adoption of vaccines and an increase in the recommendation of vaccination by different government regulatory bodies are expected to drive the market over the forecast period. For instance, in February 2019, the U.K. Joint Committee of Vaccination and Immunization (JCVI) has recommended the use of the recombinant vaccine to prevent shingles in adults aged 60 to 70 years old.

The inclusion of shingles vaccines in national immunization programs of several countries is anticipated to propel the demand for vaccines. For instance, the shingles vaccine is a part of the national immunization program in the U.K. since 2013. The U.K. is the first country in the European region to introduce shingles vaccine in the national immunization program and it costs around USD 130 to the National Health Service (NHS) for each dose of the vaccine. Similarly, other countries such as the U.S., Italy, Australia, and some provinces of Canada and South Korea have also included the vaccine in their immunization program.

Besides, favorable initiatives undertaken by market players and regulatory bodies to increase the awareness among people who are at risk of developing the disease are expected to fuel the market growth over the coming years. For instance, GlaxoSmithKline plc. has launched a campaign to increase vaccination rates among older adults by educating people about the benefits associated with vaccination.

The high efficacy of vaccines is expected to increase the adoption over the forecast period. According to clinical trial results, Shingrix is highly efficient to prevent shingles and postherpetic neuralgia. Two doses of Shingrix are more than 90% effective to prevent the disease in adults aged 50 years and above. Protection stays above 85% for at least the first four years after getting vaccinated.

The availability of vaccines at lower prices, coupled with a high incidence of the disease and high vaccination rate in developed countries, is anticipated to fuel the market growth. The vaccination rate against shingles in the U.K., the U.S., France, Canada, Germany, and South Korea is higher compared to other countries owing to better reimbursement policies and high awareness levels regarding the disease and vaccines. For instance, the U.K. has the highest shingles vaccine uptake with more than 60% vaccination of eligible adults.

Shingles Vaccine Market Report Highlights:

  • By product, Shingrix held the largest share in 2023, owing to the high efficacy of the vaccine as compared to others. Shingrix is also expected to grow at a significant CAGR over the forecast period owing to the increasing recommendations by regulatory bodies to prevent shingles
  • Based on vaccine type, the recombinant vaccine segment is anticipated to grow at a substantial rate over the forecast period due to the low risk associated with recombinant vaccines
  • Asia Pacific is projected to witness the fastest growth during the forecast period owing to the high unmet needs and the rising adoption of vaccination programs in the region
  • North America dominated the market in 2023, due to favorable reimbursement policies and rising initiatives to raise awareness among healthcare professionals and patients.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Type outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Shingles Vaccine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing risk of developing shingles
      • 3.2.1.2. Increase in recommendation of shingles vaccine
      • 3.2.1.3. Cost - effectiveness of shingles vaccine
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Low awareness regarding shingles
      • 3.2.2.2. Weak product pipeline
  • 3.3. Shingles Vaccine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Shingles Vaccine Market: Product Estimates & Trend Analysis

  • 4.1. Global Shingles Vaccine Market: Product Dashboard
  • 4.2. Global Shingles Vaccine Market: Product Movement Analysis
  • 4.3. Global Shingles Vaccine Market by Product, Revenue
  • 4.4. Shingrix
    • 4.4.1. Shingrix market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Zostavax
    • 4.5.1. Zostavax market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. SKYZoster
    • 4.6.1. SKYZoster market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Shingles Vaccine Market: Type Estimates & Trend Analysis

  • 5.1. Global Shingles Vaccine Market: Type Dashboard
  • 5.2. Global Shingles Vaccine Market: Type Movement Analysis
  • 5.3. Global Shingles Vaccine Market Estimates and Forecasts, By Type, Revenue (USD Million)
  • 5.4. Recombinant Vaccine
    • 5.4.1. Recombinant Vaccine market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Live Attenuated Vaccine
    • 5.5.1. Live Attenuated Vaccine market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Shingles Vaccine Market: End Use Estimates & Trend Analysis

  • 6.1. Global Shingles Vaccine Market: End Use Dashboard
  • 6.2. Global Shingles Vaccine Market: End Use Movement Analysis
  • 6.3. Global Shingles Vaccine Market Estimates and Forecasts, by End Use, Revenue (USD Million)
  • 6.4. Private Healthcare Settings
    • 6.4.1. Private Healthcare Settings market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Government Healthcare Settings
    • 6.5.1. Government Healthcare Settings market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Shingles Vaccine Market: Regional Estimates & Trend Analysis by Product, Type, End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key customers
    • 8.2.3. Key company market share analysis, 2023
    • 8.2.4. GlaxoSmithKline plc.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Merck & Co., Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. SK chemicals
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Green Cross Corp
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Geneone Life Science
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Vaccitech
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. CanSinoBIO
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Shingles vaccine market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 5 U.S. shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 8 Canada shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 9 Canada shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Mexico shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 12 Mexico shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 13 Mexico shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Europe shingles vaccine market, by region, 2018 - 2030 (USD Million)
  • Table 15 Europe shingles vaccine market, byproduct, 2018 - 2030 (USD Million)
  • Table 16 Europe shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 17 Europe shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Germany shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 19 Germany shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 20 Germany shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 21 UK shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 22 UK shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 23 UK shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 24 France shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 25 France shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 26 France shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 27 Italy shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 28 Italy shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 29 Italy shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Spain shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 31 Spain shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 32 Spain shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Denmark shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 34 Denmark shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 35 Denmark shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Sweden shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 37 Sweden shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 38 Sweden shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Norway shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 40 Norway shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 41 Norway shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific shingles vaccine market, by region, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 45 Aisa Pacific shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 46 China shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 47 China shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 48 China shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 49 Japan shingles vaccine market, byproduct, 2018 - 2030 (USD Million)
  • Table 50 Japan shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 51 Japan shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 52 India shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 53 India shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 54 India shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 55 South Korea shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 56 South Korea shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 57 South Korea shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 58 Australia shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 59 Australia shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 60 Australia shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Thailand shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 62 Thailand shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 63 Thailand shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 64 Latin America shingles vaccine market, by region, 2018 - 2030 (USD Million)
  • Table 65 Latin America shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 66 Latin America shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 67 Latin America shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 68 Brazil shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 69 Brazil shingles vaccine market, by vaccine product, 2018 - 2030 (USD Million)
  • Table 70 Brazil shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 71 Argentina shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 72 Argentina shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 73 Argentina shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 74 MEA shingles vaccine market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 76 MEA shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 77 MEA shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 78 South Africa shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 79 South Africa shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 80 South Africa shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 84 UAE shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 85 UAE shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 86 UAE shingles vaccine market, by end use, 2018 - 2030 (USD Million)
  • Table 87 Kuwait shingles vaccine market, by product, 2018 - 2030 (USD Million)
  • Table 88 Kuwait shingles vaccine market, by type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait shingles vaccine market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Shingles vaccine market: market outlook
  • Fig. 14 Shingles vaccine market competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Shingles vaccine market driver impact
  • Fig. 18 Shingles vaccine market restraint impact
  • Fig. 19 Shingles vaccine market: Product movement analysis
  • Fig. 20 Shingles vaccine market: Product outlook and key takeaways
  • Fig. 21 Shingrix market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Zostavax market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 SKYZoster market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Shingles vaccine market: Vaccine type movement analysis
  • Fig. 25 Shingles vaccine market: Vaccine type outlook and key takeaways
  • Fig. 26 Recombinant Vaccine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Live Attenuated Vaccine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Shingles vaccine market: End Use movement analysis
  • Fig. 29 Shingles vaccine market: End Use outlook and key takeaways
  • Fig. 30 Private Healthcare Settings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Government Healthcare Settings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Global Shingles vaccine market: Regional movement analysis
  • Fig. 33 Global Shingles vaccine market: Regional outlook and key takeaways
  • Fig. 34 Global Shingles vaccine market share and leading players
  • Fig. 35 North America, by country
  • Fig. 36 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. key country dynamics
  • Fig. 38 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Canada key country dynamics
  • Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico key country dynamics
  • Fig. 42 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 UK key country dynamics
  • Fig. 45 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Germany key country dynamics
  • Fig. 47 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 France key country dynamics
  • Fig. 49 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Italy key country dynamics
  • Fig. 51 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Spain key country dynamics
  • Fig. 53 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Denmark key country dynamics
  • Fig. 55 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden key country dynamics
  • Fig. 57 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Norway key country dynamics
  • Fig. 59 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 China key country dynamics
  • Fig. 62 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Japan key country dynamics
  • Fig. 64 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 India key country dynamics
  • Fig. 66 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Thailand key country dynamics
  • Fig. 68 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea key country dynamics
  • Fig. 70 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Australia key country dynamics
  • Fig. 72 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Brazil key country dynamics
  • Fig. 75 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Argentina key country dynamics
  • Fig. 77 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa key country dynamics
  • Fig. 80 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia key country dynamics
  • Fig. 82 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 UAE key country dynamics
  • Fig. 84 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait key country dynamics
  • Fig. 86 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Market share of key market players- Shingles vaccine market